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RESUMO
Introdução: Os agentes biossimilares são cópias muito semelhantes de agentes biológicos originais previamente aprovados. A sua 
introdução no mercado tem como objetivo reduzir custos. O objetivo deste estudo foi avaliar as perspetivas dos doentes com psoríase 
sobre os medicamentos biossimilares. 
Material e Métodos: Foi realizado um inquérito com 14 questões em doentes com psoríase medicados com agentes biológicos e 
seguidos num Serviço de Dermatologia de um hospital terciário português. 
Resultados: Dos 108 doentes incluídos, 70,4% desconheciam a definição de agente biossimilar e 76,6% mostraram interesse parcial 
ou total no uso de medicamentos biossimilares. Perto de 80% concordaram com o uso de agentes biossimilares de modo a reduzir 
os custos associados às terapêuticas biológicas. Contudo, a ausência de estudos na população europeia e em doentes com psoríase 
levaram a maioria dos doentes (72,2% e 75,0%, respetivamente) a oporem-se, parcial ou totalmente, ao uso dos medicamentos 
biossimilares. Dados demográficos, rendimento mensal e tipo de terapêutica biológica não influenciaram as preferências dos doentes. 
Discussão: Apesar do desconhecimento dos participantes sobre os medicamentos biossimilares, a maioria dos doentes parece 
recetiva à sua utilização. Todavia, existem dois motivos de preocupação: i) o uso de medicamentos biossimilares que não foram 
testados na população europeia, e ii) a sua aprovação para a psoríase sem estudos nesta doença. Assim, é necessário fornecer mais 
informação aos doentes sobre os medicamentos biossimilares.
Conclusão: Os biossimilares podem aumentar o acesso dos doentes a terapêuticas biológicas. Melhor comunicação e o envolvimento 
dos doentes na tomada de decisões relativamente aos medicamentos biossimilares pode aumentar a adesão no futuro. 
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ABSTRACT
Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market 
may yield cost reduction. The aim of this study was to evaluate the perspectives of psoriasis patients on biosimilar medications.
Materials and Methods: We conducted a 14 questions survey of psoriasis patients receiving biological therapy and followed-up in a 
dermatology department of a Portuguese tertiary care hospital. 
Results: From a total of 108 patients included, 70.4% of patients did not know the definition of biosimilar agent and 76.6% of patients 
showed partial or total interest in using a biosimilar drug. Nearly 80% of patients partially or totally agreed in using a biosimilar 
drug in order to reduce healthcare costs with psoriasis treatment. However, the lack of studies in the European population and in 
psoriatic patients led most of the patients (72.2% and 75.0%, respectively) to somewhat or completely oppose to the use of biosimilars. 
Demographic variables, household income and type of current biologic therapy did not affect patient preferences.
Discussion: Despite of the unfamiliarity of the respondents with biosimilars, most patients seem receptive to their use. Nevertheless, 
there are two issues of concern: i) the use of biosimilars that are not tested in a European population, and ii) its approval for psoriasis 
without trials in this disease. Thus, an immediate need exists for patient education about biosimilars.
Conclusion: Biosimilars may increase patient access to biologic therapies. Improved communication and the involvement of patients 
in decision-making regarding biosimilars may increase their acceptance in future.
Keywords: Biological Therapy; Biosimilar Pharmaceuticals; Psoriasis/therapy
INTRODUCTION
 Psoriasis is a chronic inflammatory and immune-
mediated skin disease with a significant physical and 
psychological burden. It is estimated to affect 250 000 
Portuguese patients.1 
 Biologic agents have revolutionized the treatment of 
psoriasis and psoriatic arthritis, providing an option to pa-
tients who were non-responsive to phototherapy and con-
ventional systemic treatments.2 However, these therapies 
impose a heavy burden on the healthcare system due to 
their high cost. In Portugal, the biologic therapy-related 
costs are 100% funded by the national healthcare system. 
 The expiration of patents and market exclusivity periods 
of originators allowed the introduction of biosimilars. Bio-
similars are defined by European Medicines Agency (EMA) 
as a ‘biological medicinal product that contains a version of 
the active substance of an already authorised original bio-
logical medicinal product (reference product).3 In order to 
be approved by regulatory agencies, biosimilars must prove 
to be highly structurally analogous to the reference drug 
and to be highly similar in terms of quality, safety, efficacy 
and immunogenicity to the originator agent.1 Biosimilars 
may cost 25% - 30% less than the original agents, as the 
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manufacturing process and development costs are con-
siderably lower. Thus, biosimilars are expected to reduce 
health care costs and to increase patient access to biologic 
therapies.
 Still, some physicians question the quality and 
safety of biosimilars and express concerns regarding 
interchangeability and extrapolation of indications.4 
Regarding patients’ perspectives towards biosimilars, many 
patients with inflammatory bowel disease (IBD) were not 
familiar with biosimilars,5 while safety is the major concern 
of patients with rheumatoid arthritis (RA).4
 This study aimed to assess Portuguese psoriasis 
patients’ knowledge about biosimilars, and the factors 
influencing their preference for originators or biosimilars.
MATERIAL AND METHODS
 We surveyed 108 consecutive Portuguese patients 
diagnosed with psoriasis and treated with biologic agents 
in the Dermatology department of Centro Hospitalar do 
Porto. The survey was conducted from January 1 through 
July 31, 2017. During this period, all patients evaluated on 
psoriasis consultation were invited by their dermatologist 
to participate in this survey. The participants were aged 
18 years or older, had a diagnosis of psoriasis and were 
treated with originator biologic agents. Patients treated with 
biossimilars medications, phototherapy or oral conventional 
systemic treatments were excluded. The survey was 
prepared based on a study of the literature and collaboration 
with dermatologists. The anonymous questionnaire 
consisted of 14 closed-ended questions. Regarding the 
internal validation of the questionnaire, Cronbach’s alpha 
was calculated to evaluate the internal consistency of the 
responses given by the patients. We assessed demographic 
data, patients’ understanding of biosimilar agents and, after 
providing a definition, patients’ opinion on the introduction 
of biosimilars. The physician did not provide any information 
about biosimilars to patients before this survey. The study 
was approved by the hospital Institutional Review Board 
and subject’s written consent was obtained.
 Descriptive statistics from qualitative data was presented 
as relative frequency per category. Stacked bars were 
used to show the percentage contribution of the different 
answers. The one sample chi-squared test was used to 
evaluate if patients have significantly different opinions in 
relation to the questions. A univariate logistic regression 
analysis of the association between the response variable 
(questions 5 to 9) and each of the demographic variables 
(age, sex, monthly household income and education) was 
executed. A multivariate logistic regression model, with 
stepwise forward selection, was performed only when 
univariate analysis was p < 0.250. To perform the logistic 
regression the dependent variable (patient’s answers), 
were grouped 1- answers a and b, and 2- answers c and d, 
in order to transform the dependent variable into binary, the 
answer e (indifferent) was excluded. As for the independent 
variables, age was used as a continuous variable; education 
(1- Primary School + Basic school and 2- Secondary school 
+ University education) and monthly household income 
(1- ≤ 530 € and 2- 531 – 1060€+1061-1590€ + > 1591€) 
were grouped. Tests were performed at a significance level 
of 0.05. All statistical analysis was performed using SPSS 
version 24.0.
RESULTS
Patients’ demographics 
 A total of 108 patients participated in this survey. Most 
patients were male (65.7%) and more than half (52.8%) of 
the participants were 40-60 years of age (Table 1). Most 
respondents had a monthly household income of less than 
1060€. Out of 108 psoriatic patients, 10.2% also had articular 
Table 1 – Patient’s demographic, economical, clinical and treatment 
characteristics  
Demographics
Participants  
(n = 108)
n %
Sex
Female 37 34.3
Male 71 65.7
Age, years
18 - 24 3 2.8
25 - 39 28 25.9
40 - 60 57 52.8
> 60 20 18.5
Education
Primary school (1th to 4th year) 17 15.7
Basic school (5th to 9th year) 27 25.0
Secondary school (10th to 12th year) 39 36.1
University education 25 23.1
Monthly household income
≤ 530€ 43 39.8
531€ – 1060€ 43 39.8
1061€ – 1590€ 16 14.8
> 1591€ 6 5.6
Diagnosis
Psoriasis without articular involvement 97 89.8
Psoriasis with articular involvement 11 10.2
Duration of biologic treatment
Less than 6 months 16 15.0
Between 6 months and 1 year 13 12.1
Between 1 and 5 years 62 57.9
More than 6 years 16 15.0
Biologic agent
Adalimumab 15 13.9
Etanercept 42 38.9
Infliximab 2 1.9
Ustekinumab 25 23.1
Secukinumab 24 22.2
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involvement. The duration of biologic therapy was between 
1 to 5 years for the majority of participants (57.9%). The 
most prescribed biologics were etanercept (38.9%) followed 
by ustekinumab (23.1%) and secukinumab (22.2%). 
Questionnaire responses
 The Cronbach’s alpha for questions five to nine was 
0.812, greater than 0.7, therefore we can assume that these 
responses have relatively good internal reliability. 
The majority of participants (70.4%) did not know what 
biosimilars were, 24.1% thought biosimilars were similar 
but not identical copies of biological medicines, 3.7% 
thought they were a new brand of a biological medicine and 
1.9% thought they were an identical copy of a biological 
medicine. After providing a definition of biosimilar, 76.6% of 
participants showed interest (somewhat or very interested) 
in using a biosimilar, while 15.0% were against their 
introduction (Fig. 1) (p < 0.001).
 Most patients (80.3%) showed interest (somewhat or 
very interested) in using a cheaper biosimilar that can allow 
for savings to the Portuguese health system. In contrast, 
13.2% of patients disagreed with the use of biosimilar agents 
even if they allowed a lower expense for the healthcare 
system (Fig. 1) (p < 0.001). If the decision of switching to 
a cheaper biosimilar comes from the hospital board given 
the potential cost savings, 79.4% of participants were in 
agreement (somewhat or totally) with that decision, while 
15.9% were somewhat or completely against the hospital’s 
decision (Fig. 1) (p < 0.001).
 Nevertheless, the lack of studies evaluating biosimilars 
in European patients led 72.2% of the patients to somewhat 
or completely oppose to biosimilar agents, while 25.0% 
maintained interest in using these drugs (Fig. 1) (p < 
0.001). Regarding the extrapolation of indications, 75.0% 
of participants were partially or completely against the 
use of a biosimilar approved in psoriasis but only tested 
in a different pathology. Solely 21.3% maintained interest 
in using biosimilars that were approved but not tested in 
psoriasis (Fig. 1) (p < 0.001). 
 Of the participants, 96.2% felt that their dermatologist’s 
opinion would somewhat or strongly influence their decision 
in starting/switching to a biosimilar drug. 
 Finally, when patients were questioned about the 
hypothesis of paying for some of the therapy-related costs, 
61.7% of participants were partially or completely interested 
in switching to a biosimilar agent in order to reduce their 
own expenses, compared with 31.8% that expressed some 
or total interest in keeping the current originator drug  (Fig. 
2) (p < 0.001).
 Logistic regression showed that demographics, 
household income, duration of biologic therapy and current 
biologic agent did not affect patient’s answers (p > 0.05).
DISCUSSION
 To our knowledge, this is the first survey addressing 
the perspectives on biosimilar agents among patients 
exclusively diagnosed with psoriasis. One of the most 
noticeable findings was the lack of patient awareness 
of biosimilars medications. Only 24.1% of participants 
were familiar with the biosimilar definition. A previous 
international cross-sectional survey showed that knowledge 
on biosimilars was low among patients with several 
inflammatory and neoplastic diseases, caregivers, and 
the general population in the US and the European, with 
only 6% – 30% reporting at least a general impression and 
up to 70% reporting they had never heard of biosimilars.6 
Figure 1 – Patients’ answers after providing a definition of biosimilar and regarding factors that might influence them to start/switch to a 
biosimilar
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Lower percentages were also identified in a survey 
conducted in European patients with IBD: solely 36.6% of 
Crohn’s disease patients and 35.5% of ulcerative colitis 
patients had previously heard of biosimilars.5 In Belgian RA 
patients, 49% of respondents were familiar with biosimilars.4 
This highlights a need for patient education about biosimilars 
in order to ensure informed decision-making.
 In our survey, most patients (76.6%) seemed receptive 
to using biosimilar agents. Notably, nearly 80% of patients 
showed interest in using a biosimilar to reduce healthcare 
costs with psoriasis treatment, even if the switch was 
determined by the hospital. This may suggest that patients 
are conscious about the economic burden of biologic 
therapy on the healthcare system, and hence are open to 
the introduction of biosimilars. 
 Clearly, there are two issues of concern among 
psoriasis patients: i) the use of biosimilars that are not 
tested in a European population, and ii) the fact that they 
are approved for psoriasis but not tested in this disease. 
Taking this into account, more than 70% of patients hesitate 
to use biosimilars. Similar concerns had been reported by 
IBD patients, as solely 13.1% of the respondents thought 
that made sense the use of biosimilars in IBD that were 
only tested in a different condition made sense.5 Many of 
the raised concerns raised regarding extrapolation may be 
hypothetical, and likely not problematic in the long term, 
considering the increasing evidence of efficacy and safety 
of biosimilars in more than one inflammatory disease.7 
Further patient education on the various issues regarding 
biosimilars would possibly clarify these doubts.
 Noteworthy, in spite of the above concerns, the 
possibility of paying some of therapy-related costs seemed 
to affect patient decision. More than 60% of participants 
were receptive to switching to a biosimilar at a lower price if 
they had to pay for their treatment. 
 Finally, almost all patients valued their physician’s 
advice to switch to or start a biosimilar. This emphasizes 
the importance of a good patient–doctor relationship, as 
depicted in a Belgian survey where 76% and 65% of RA 
patients accepted starting or switching to a biosimilar on 
their doctor’s advice, respectively.4 
 Our study presents some limitations. The selection of 
participants was limited to psoriasis patients receiving 
biologic therapy and followed-up in a public dermatology 
department. Therefore, generalization of findings warrants 
caution. It would be interesting to evaluate the opinion 
of patients under other treatments like topical therapy, 
phototherapy or conventional systemic agents. The 
relatively low sample size may not allow the identification of 
associations with statistical significance. The extrapolation 
concept may be difficult to grasp for a patient with no 
scientific background, and this should be considered 
when interpreting the results. Because the complexity of 
other concepts such as interchangeability and automatic 
substitution, patients were not specifically asked about 
their opinion on these topics. Nevertheless, healthcare 
professionals should provide patients with the necessary 
information to allow informed decision-making about the 
use of biosimilars.  
CONCLUSION
 Our survey suggests that most psoriatic patients are 
not familiar with biosimilars and emphasizes the need for 
further patient education. Most patients seem receptive to 
using biosimilar agents but are hesitant to use biosimilars 
not tested in European population and in psoriatic patients. 
The possibility of paying for some of the therapy-related 
costs seems to affect patient decision. Physician’s advice 
is important for patient decision. Improved communication 
and reassurance by dermatologists and the involvement 
of patients in decision-making regarding biosimilars may 
increase their acceptance in future.
PROTECTION OF HUMAN AND ANIMAL SUBJECTS
 The authors declare that the research procedures were 
performed according to the regulations of the institution’s 
ethics committee and the Code of Ethics of the World 
Medical Association (Declaration of Helsinki).
Figure 2 – Patients’ answers to the final question regarding the hypothetical scenario of having to pay for some of the therapy-related costs
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